Current Value
$18.491 Year Return
Current Value
$18.491 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -27.77% | $185.08M | 0.85% |
TAIL | -26.79% | $101.78M | 0.59% |
IVOL | -20.92% | $349.05M | 1.02% |
BTAL | -19.96% | $291.48M | 1.43% |
XHLF | -15.19% | $1.72B | 0.03% |
TPMN | -13.98% | $30.91M | 0.65% |
CTA | -11.51% | $1.09B | 0.76% |
CLIP | -9.59% | $1.51B | 0.07% |
STPZ | -9.43% | $445.04M | 0.2% |
TDTT | -9.28% | $2.61B | 0.18% |
VTIP | -8.67% | $15.17B | 0.03% |
STIP | -8.31% | $12.62B | 0.03% |
CANE | -7.86% | $9.87M | 0.29% |
UTWO | -7.85% | $372.79M | 0.15% |
XONE | -7.59% | $640.90M | 0.03% |
IBTF | -6.88% | $2.07B | 0.07% |
ULST | -6.88% | $668.01M | 0.2% |
GSST | -6.58% | $900.18M | 0.16% |
PALL | -6.40% | $474.94M | 0.6% |
IBTH | -6.36% | $1.58B | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IRON | 48.25% | $1.73B | +15.04% | 0.00% |
IMNM | 46.80% | $768.32M | -33.51% | 0.00% |
ZYME | 45.38% | $887.30M | +48.24% | 0.00% |
ZNTL | 44.96% | $99.29M | -66.67% | 0.00% |
OCUL | 44.49% | $1.33B | +51.73% | 0.00% |
IDYA | 42.98% | $1.91B | -41.35% | 0.00% |
SNDX | 42.01% | $833.80M | -49.16% | 0.00% |
RCUS | 41.97% | $901.08M | -46.78% | 0.00% |
RNA | 40.47% | $3.53B | -23.51% | 0.00% |
STOK | 40.45% | $631.69M | -23.23% | 0.00% |
SYRE | 40.22% | $910.13M | -41.53% | 0.00% |
CATX | 40.19% | $256.09M | -71.08% | 0.00% |
OVID | 40.12% | $21.04M | -62.44% | 0.00% |
APGE | 39.83% | $2.45B | +13.23% | 0.00% |
RVMD | 39.75% | $7.44B | +5.86% | 0.00% |
DNTH | 39.51% | $560.87M | -29.90% | 0.00% |
NRIX | 39.21% | $885.86M | -36.98% | 0.00% |
BEAM | 38.48% | $1.71B | -26.67% | 0.00% |
XENE | 38.46% | $2.45B | -12.00% | 0.00% |
VRDN | 38.24% | $1.22B | +23.15% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SCHP | 0.10% | $12.80B | 0.03% |
STOT | -0.25% | $248.21M | 0.45% |
NEAR | 0.33% | $3.29B | 0.25% |
IBTL | -0.36% | $374.15M | 0.07% |
CGSD | -0.43% | $1.30B | 0.25% |
TYA | -0.62% | $147.80M | 0.15% |
IEF | 0.62% | $34.13B | 0.15% |
BILZ | 0.65% | $840.74M | 0.14% |
BWX | 0.66% | $1.47B | 0.35% |
TIP | 0.66% | $13.66B | 0.18% |
GVI | 0.73% | $3.38B | 0.2% |
BIL | 0.86% | $43.95B | 0.1356% |
TIPZ | 0.89% | $96.50M | 0.2% |
FLGV | 0.90% | $995.15M | 0.09% |
IBTO | 0.95% | $341.53M | 0.07% |
PPLT | -1.05% | $1.52B | 0.6% |
XBIL | -1.05% | $795.25M | 0.15% |
SPTI | -1.20% | $8.63B | 0.03% |
PTBD | 1.25% | $145.18M | 0.6% |
AGZ | 1.33% | $608.84M | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 49.05% | $4.66B | 0.35% |
IBB | 46.69% | $5.44B | 0.45% |
GNOM | 45.92% | $43.17M | 0.5% |
BBH | 40.81% | $336.53M | 0.35% |
PBE | 39.97% | $222.71M | 0.58% |
ARKG | 38.56% | $1.02B | 0.75% |
FBT | 38.50% | $997.89M | 0.54% |
IWC | 38.25% | $801.78M | 0.6% |
IWO | 37.16% | $11.30B | 0.24% |
IWM | 36.80% | $62.96B | 0.19% |
VTWO | 36.64% | $12.19B | 0.07% |
KJUL | 36.52% | $117.87M | 0.79% |
PTH | 36.24% | $101.31M | 0.6% |
KJAN | 35.98% | $284.74M | 0.79% |
SCHA | 35.86% | $16.76B | 0.04% |
XPH | 35.77% | $148.95M | 0.35% |
NUSC | 35.42% | $1.11B | 0.31% |
IWN | 35.39% | $10.76B | 0.24% |
ESML | 34.90% | $1.78B | 0.17% |
ISCG | 34.90% | $662.94M | 0.06% |
Yahoo
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Yahoo
As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Neurogene (NGNE) with a Buy rating and $50 price target. The firm notes the company is developing NGN-401, an AAV gene therapy for Rett syndrome, a rare and devastating neurodevelopmental disease that impacts girls beginning in infancy and is characterized by developmental regression and symptoms that require lifelong care. Craig-Hallum believes Neurogene is undervalued and that NGN-401 has an elegant design that give
Finnhub
NGN-401 Gene Therapy for Rett Syndrome Clinical Program 2025 IRSF Rett Syndrome Scientific Meeting ...
Finnhub
Corporate Presentation June 2025 ...
Yahoo
NEW YORK, June 06, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company’s common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement
Yahoo
Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the data from our partner Ortex.com, which utilizes the latest information from stock lenders to estimate short interest changes for thousands of publicly traded companies, this report will screen for some of biggest changes in short interest as a percentage of free float and days-to-cover ratios while also consi
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BTCT | -27.13% | $19.62M | +36.77% | 0.00% |
MNOV | -12.09% | $62.29M | -3.05% | 0.00% |
CBOE | -10.34% | $23.83B | +34.36% | 1.10% |
ACRS | -10.23% | $153.76M | +25.66% | 0.00% |
DFDV | -8.36% | $460.68M | +2,996.21% | 0.00% |
OXBR | -8.00% | $12.58M | -29.29% | 0.00% |
BCE | -7.02% | $20.10B | -32.92% | 11.20% |
DRD | -6.60% | $1.22B | +67.74% | 1.99% |
FMTO | -6.25% | $4.80K | -99.92% | 0.00% |
GFI | -5.80% | $21.77B | +73.47% | 2.28% |
NXTC | -5.17% | $12.70M | -65.71% | 0.00% |
HMY | -5.03% | $8.95B | +63.97% | 1.21% |
K | -4.11% | $27.39B | +34.25% | 2.89% |
SE | -3.93% | $85.08B | +104.10% | 0.00% |
EDSA | -3.69% | $14.29M | -52.23% | 0.00% |
IAG | -3.58% | $4.18B | +93.87% | 0.00% |
CORT | -3.32% | $7.55B | +153.07% | 0.00% |
CCRN | -3.13% | $467.16M | +0.64% | 0.00% |
NEUE | -2.86% | $61.16M | +29.49% | 0.00% |
HUSA | -2.74% | $27.45M | +41.13% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LEU | 0.01% | $3.08B | +334.06% | 0.00% |
MSIF | 0.11% | $824.63M | +45.84% | 6.11% |
OMI | -0.14% | $571.54M | -56.35% | 0.00% |
LTM | -0.18% | $11.48B | -96.27% | 2.65% |
TGI | -0.26% | $2.00B | +80.84% | 0.00% |
FTS | 0.26% | $23.74B | +23.03% | 3.69% |
SMLR | -0.27% | $356.18M | -14.26% | 0.00% |
NYT | 0.36% | $8.81B | +8.29% | 1.05% |
ED | -0.40% | $36.29B | +11.44% | 3.33% |
DOGZ | -0.41% | $375.43M | +86.17% | 0.00% |
TU | 0.41% | $24.43B | +2.89% | 7.17% |
KNOP | 0.42% | $233.22M | -2.16% | 1.52% |
MO | -0.42% | $100.21B | +32.79% | 6.87% |
EQT | -0.45% | $35.54B | +55.42% | 1.06% |
PINC | -0.45% | $1.83B | +22.50% | 3.75% |
TPB | -0.46% | $1.33B | +129.02% | 0.29% |
AWK | -0.47% | $27.52B | +8.15% | 2.21% |
FUBO | 0.57% | $1.08B | +167.80% | 0.00% |
T | 0.58% | $199.03B | +53.24% | 4.01% |
TEF | 0.58% | $29.46B | +22.25% | 9.27% |